Pentoxifylline for the treatment of nonalcoholic fatty liver disease

Ratziu, 2010, A position statement on NAFLDNASH based on the EASL 2009 special conference., J Hepatol, 53, 372, 10.1016/j.jhep.2010.04.008

Zhang, 2012, Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism., PloS One, 7, e51131, 10.1371/journal.pone.0051131

Mahady, 2012, Management of nonalcoholic steatohepatitis: an evidence-based approach., Clin Liver Dis, 16, 631, 10.1016/j.cld.2012.05.003

Boettcher, 2012, Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis., Aliment Pharmacol Ther, 35, 66, 10.1111/j.1365-2036.2011.04912.x

Braunersreuther, 2012, Role of cytokines and chemokines in non-alcoholic fatty liver disease., World J Gastroenterol, 18, 727, 10.3748/wjg.v18.i8.727

Koca, 2008, The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet., Inflammation, 31, 91, 10.1007/s10753-007-9053-z

Koppe, 2004, Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet., J Hepatol, 41, 592, 10.1016/j.jhep.2004.06.030

Adams, 2004, A pilot trial of pentoxifylline in nonalcoholic steatohepatitis., Am J Gastroenterol, 99, 2365, 10.1111/j.1572-0241.2004.40064.x

Li, 2011, Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease., Lipids Health Dis, 10, 49, 10.1186/1476-511X-10-49

Gu, 2013, Antioxidant supplementation for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials., Nutr J, 12, 23, 10.1186/1475-2891-12-23

Zeng, 2012, A meta-analysis of randomized, double-blind, placebo-controlled trials for the effects of garlic on serum lipid profiles., J Sci Food Agric, 92, 1892, 10.1002/jsfa.5557

Brunt, 1999, Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions., Am J Gastroenterol, 94, 2467, 10.1111/j.1572-0241.1999.01377.x

Higgins, 2003, Measuring inconsistency in meta-analyses., BMJ, 327, 557, 10.1136/bmj.327.7414.557

Buranawati, 2007, Pentoxifylline for treatment of nonalcoholic fatty liver disease (NAFLD): a randomized, placebo-controlled study., Thai J Gastroenterol, 8, 57

Amin, 2009, Effect of pentoxifylline on serum hyaluronic acid in patients with non-alcoholic fatty liver disease., Arab J Gastroenterol, 10, 102, 10.1016/j.ajg.2009.09.001

Smith, 2011, Non-alcoholic fatty liver disease., Crit Rev Clin Lab Sci, 48, 97, 10.3109/10408363.2011.596521

Dowman, 2011, Current therapeutic strategies in non-alcoholic fatty liver disease., Diabetes Obes Metab, 13, 692, 10.1111/j.1463-1326.2011.01403.x

Xiao, 2013, Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges., Hepatobiliary Pancreat Dis Int, 12, 125, 10.1016/S1499-3872(13)60021-1

Mukhopadhyay, 2006, Role of TNFalpha in pulmonary pathophysiology., Respir Res, 7, 125, 10.1186/1465-9921-7-125

Lin, 2004, Pharmacological modulation of TNF production in macrophages., J Microbiol Immunol Infect, 37, 8

Tong, 2004, Extrinsic allergic alveolitis: inhibitory effects of pentoxifylline on cytokine production by alveolar macrophages., Ann Allergy Asthma Immunol, 92, 234, 10.1016/S1081-1206(10)61553-0

Akriviadis, 2000, Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial., Gastroenterology, 119, 1637, 10.1053/gast.2000.20189

Sumida, 2013, Involvement of free radicals and oxidative stress in NAFLDNASH., Free Radic Res, 47, 869, 10.3109/10715762.2013.837577